Everything below concerns melanogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Herein, the total number of carbons about the fatty acid is listed prior to the total number of double bonds present within the molecule, and is generally formatted as is seen in Example 1. for palmitic acid (C16:0) and palmitoleic acid (C16:1).
This meeting had been approved at the highest levels of both governments because each side had something the other wanted very badly: the Soviets wanted to know exactly why Boeing had put the 747 engines in under-wing pods instead of at the rear of the fuselage, while Withington and the Boeing engineers had a long list of questions about the processing and use of titanium in airframes (at the time Boeing badly needed this for their proposed Boeing 2707 SST, at Mach 3 too fast and hot for Concorde-style aluminium, and the Soviets then led the world in titanium technology). According to Sutter's account, both sides left the meeting well satisfied with the exchange of information. It seems (again according to Sutter's account of the aftermath) that this meeting may have made a real difference to Soviet aircraft design, but Boeing's contribution could naturally not be acknowledged publicly by the Soviet side. Ilyushin therefore had to stress that it had been the first in the world to use podded engines suspended from pylons beneath and ahead of the wing, on the experimental Ilyushin Il-22 four-engined jet bomber of 1946 (first use of this designation). Having thus presented the Il-86's ultimate configuration as indigenously Soviet, the bureau could at last show it in public in 1973, six years after publication of the aerobus specification and four years after the design assignment. A modern six-window flightdeck followed, in place of the 18-to-20 window glazing of the Il-18, Il-62 and Il-76. The main problem facing the Il-86 project was the lack of a suitable engine.
The protein component of AGPs is rich in the amino acids Proline (P), Alanine (A), Serine (S) and Threonine (T), also known as 'PAST', and this amino acid bias is one of the features used to identify them. AGPs are intrinsically disordered proteins as they contain a high proportion of disordering amino acids such as Proline that disrupt the formation of stable folded structures. Characteristic of intrinsically disordered proteins, AGPs also contain repeat motifs and post-translational modifications. Proline residues in the protein backbone can be hydroxylated to Hydroxyproline (O) depending on the surrounding amino acids. The 'Hyp contiguity hypothesis' predicts that when O occurs in a non-contiguous manner, for example the sequence 'SOTO', such as occurs in AGPs, this acts as a signal for O-linked glycosylation of large branched type II arabinogalactan (AG) polysaccharides. Sequences that direct AG glycosylation (SO, TO, AO, VO) are called AGP glycomotifs. All AGP protein backbones contain a minimum of 3 clustered AGP glycomotifs and an N-terminal signal peptide that directs the protein into the endoplasmic reticulum (ER) where post-translational modifications begin. Prolyl hydroxylation of P to O is fulfilled by prolyl 4-hydroxylases (P4Hs) belonging to the 2-oxoglutarate dependant dioxygenase family. P4H has been identified in both the ER and Golgi apparatus. The addition of the glycosylphosphatidylinositol (GPI)-anchor occurs in most but not all AGPs.
Sources: en.wikipedia.org
The body or shaft of the penis is the free portion of the human penis that is located outside of the pelvic cavity. It is the suspended middle portion of the organ, continuous proximally with the internal root and distally with the glans. Unlike the root, the body contains no muscle, consisting mostly of the corpora cavernosa, the corpus spongiosum and the spongy urethra, together with supporting skin, connective tissue, blood and lymphatic vessels and fascia. The corpora cavernosa are intimately bound to one another with a dorsally fenestrated septum, which becomes a complete one before the penile crura. The body of the penis is homologous to the female clitoral body.
These studies have produced models of protein adhesive and other biopolymer deteriorations and the concurrent pore system development. The reduction in bodily repair capability during aging is important to studies of senescence and age-associated disease, and allows the determination of age in living animals. Forensic science can use this technique to estimate the age of a cadaver or an objet d'art to determine authenticity.
Djalikatou Diallo- former vice-president Guinean Football Federation, former vice-president Nation Assembly, former Minister of National unity and Citizenship. Diaka Sidibé- former Minister of Higher Education, Scientific Research and Innovation, former Minister of Trade, Industry and Small and Medium-sized Enterprises. Kadiatou Émilie Diaby - former Minister of Public Works. Ibrahima Abé Sylla - Minister of Energy, Hydropower and Hydrocarbons, Guinea. Aïssatou Bobo Baldé - former vice president National Assembly. Barry Diawadou – Civil clerk and politician, former member of the French National Assembly and former Minister of Education. Guinea Mamoudou Nagnalen Barry - former minister of Agriculture. Sidibé Fatoumata Kaba (diplomat) - former minister of foreign affairs, former permanent Representative to the African union And The United Nations, former ambassador to Nigeria, Ethiopia. Ambassador to the united states, Guinea. Mama Kanny Diallo - Economist, former Minister of Planning and Economic Development, Guinea. Saifoulaye Diallo –Politician and lawmaker, former member of the French National Assembly, former president of the Territorial Assembly and President of the National Assembly; former Minister of State (foreign affairs, finance, social services). Elhadj Gando Barry - former Minister of Infrastructure and Public Works, CEO Électricité de Guinée. Ibrahima Barry (popularly known as Barry III) – Lawyer and politician, former Minister from Guinea Oumar Diouhé Bah - Minister of Health and public hygiene, Guinea.
Sources: en.wikipedia.org
The traditional kava beverage is prepared through aqueous extraction of the fresh or dried roots of the Piper methysticum plant. When using fresh roots, the outer layer is typically peeled before the root is either chewed or mechanically ground into a fine, fibrous pulp, which is then mixed with water. For dried roots, the material is finely ground, placed in a porous cloth, and infused in water. The resulting brew is usually consumed immediately after preparation, often from a communal bowl. Traditional and recreational preparation of kava beverage involves macerating, grinding, or pounding fresh or dried rhizome/root (1.0–1.5 g) and mixing it with water or coconut milk (100–150 mL) to form an emulsion, which is then agitated and strained through cloth or bark filters into a communal bowl. The resulting drink is grey and slightly pungent, with fresh rhizome/root producing a stronger and more complex beverage than dried forms due to the retention of volatile compounds. In Vanuatu, fresh root is commonly used, while in non-Pacific countries, kava is typically prepared from dried root powder soaked in water (about one tablespoon per cup) for 30 minutes before straining. On Pohnpei in Micronesia, preparation also includes mixing the kava root with the fibrous bark of Hibiscus tiliaceus before pressing.
Apixaban, sold under the brand name Eliquis among others, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. It is used as an alternative to warfarin to prevent blood clots following hip or knee replacement and in those with a history of prior clots and does not require monitoring by blood tests or dietary restrictions. It is taken by mouth. Common side effects include bleeding and nausea. Other side effects may include bleeding around the spine and allergic reactions. Use is not recommended during pregnancy or breastfeeding. Use appears to be relatively safe in those with mild kidney problems. Compared to warfarin it has fewer interactions with other medications. It is a direct factor Xa inhibitor. In 2007, Pfizer and Bristol-Myers Squibb began the development of apixaban as an anticoagulant. Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 28th most commonly prescribed medication in the United States, with more than 19 million prescriptions. It is available as a generic medication, although not in the United States.
The propionyl-CoA is later converted into succinyl-CoA through biotin-dependant propionyl-CoA carboxylase (PCC) and Vitamin B12-dependant methylmalonyl-CoA mutase (MCM), sequentially. Succinyl-CoA is first converted to malate, and then to pyruvate where it is then transported to the matrix to enter the citric acid cycle. In the liver oxaloacetate can be wholly or partially diverted into the gluconeogenic pathway during fasting, starvation, a low carbohydrate diet, prolonged strenuous exercise, and in uncontrolled type 1 diabetes mellitus. Under these circumstances, oxaloacetate is hydrogenated to malate, which is then removed from the mitochondria of the liver cells to be converted into glucose in the cytoplasm of the liver cells, from where it is released into the blood. In the liver, therefore, oxaloacetate is unavailable for condensation with acetyl-CoA when significant gluconeogenesis has been stimulated by low (or absent) insulin and high glucagon concentrations in the blood. Under these conditions, acetyl-CoA is diverted to the formation of acetoacetate and beta-hydroxybutyrate. Acetoacetate, beta-hydroxybutyrate, and their spontaneous breakdown product, acetone, are frequently, but confusingly, known as ketone bodies (as they are not "bodies" at all, but water-soluble chemical substances). The ketones are released by the liver into the blood.
The city has 99 sports facilities including 46 gymnasiums, 23 sports fields, and 5 swimming pools. The Stade Océane (Ocean Stadium), inaugurated in July 2012, replaced the Stade Jules Deschaseaux. With 25,000 seats, it can host football matches as well as other sporting and cultural events. Basketball and Handball matches are playued in the Dock Océane hall (3600 seats) while ice hockey is played at the ice hockey rink (900 seats). Of the five swimming pools in the city, two are operated by the municipality: the CNH (which has an Olympic pool for competitions) and Les Bains Des Docks (which was designed by the architect Jean Nouvel). Le Havre has the largest free outdoor skatepark in France with approximately 7,000 m2 allocated to the urban Boardsport. The port infrastructure allows for many water activities such as sailing, fishing, canoeing, and rowing. Finally, the beach is a place for kitesurfing, windsurfing and surfing.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.